Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?
Identifieur interne : 000735 ( Main/Exploration ); précédent : 000734; suivant : 000736Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?
Auteurs : Justine Renaud [Canada] ; Seyed Fazel Nabavi [Iran] ; Maria Daglia [Italie] ; Seyed Mohammad Nabavi [Iran] ; Maria-Grazia Martinoli [Canada]Source :
- Rejuvenation research [ 1557-8577 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Catechin.
- chemical , therapeutic use : Catechin.
- drug therapy : Parkinson Disease.
- Humans, Prognosis.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease, and it is characterized by the loss of the neurotransmitter dopamine and neuronal degeneration in the substantia nigra pars compacta. Thus far, current therapeutic strategies have failed to address neuronal degeneration. It has been reported that overproduction of reactive oxygen species, resulting in oxidative stress, and neuroinflammation play an important role in neurodegenerative diseases through the induction of macromolecular oxidative damage and modulation of intracellular signaling pathways concurring to neuronal cell death. Indeed, anti-oxidant and anti-inflammatory drugs have been the subject of recommendation as a complementary therapy alongside an effective symptomatic treatment to hamper the progression of PD. Today, much attention is paid to polyphenols in light of their potent capacity to reduce oxidative stress and inflammation, while having much fewer side effects than most other drugs. Camellia sinensis L. is the most common ancient herbal tea prepared as a beverage worldwide and it possesses numerous beneficial effects on human health. Epigallocatechin-3-gallate is the best-known bioactive component of C. sinensis and is recognized to exert potent neuroprotective effects against oxidative stress, neuroinflammation, protein aggregation, autophagy, and neuronal cell death in vitro as well as in vivo. The present review appraises the available literature on the beneficial role of epigallocatechin-3-gallate pertaining to dopaminergic degeneration characteristic of PD with particular emphasis on its possible mechanisms of action.
DOI: 10.1089/rej.2014.1639
PubMed: 25625827
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000493
- to stream PubMed, to step Curation: 000493
- to stream PubMed, to step Checkpoint: 000493
- to stream Ncbi, to step Merge: 001A45
- to stream Ncbi, to step Curation: 001A45
- to stream Ncbi, to step Checkpoint: 001A45
- to stream Main, to step Merge: 000736
- to stream Main, to step Curation: 000735
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?</title><author><name sortKey="Renaud, Justine" sort="Renaud, Justine" uniqKey="Renaud J" first="Justine" last="Renaud">Justine Renaud</name><affiliation wicri:level="1"><nlm:affiliation>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec, Canada .</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Nabavi, Seyed Fazel" sort="Nabavi, Seyed Fazel" uniqKey="Nabavi S" first="Seyed Fazel" last="Nabavi">Seyed Fazel Nabavi</name><affiliation wicri:level="1"><nlm:affiliation>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran, Iran .</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Daglia, Maria" sort="Daglia, Maria" uniqKey="Daglia M" first="Maria" last="Daglia">Maria Daglia</name><affiliation wicri:level="1"><nlm:affiliation>3 Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia , Italy .</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>3 Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia </wicri:regionArea><wicri:noRegion>University of Pavia </wicri:noRegion></affiliation></author><author><name sortKey="Nabavi, Seyed Mohammad" sort="Nabavi, Seyed Mohammad" uniqKey="Nabavi S" first="Seyed Mohammad" last="Nabavi">Seyed Mohammad Nabavi</name><affiliation wicri:level="1"><nlm:affiliation>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran, Iran .</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Martinoli, Maria Grazia" sort="Martinoli, Maria Grazia" uniqKey="Martinoli M" first="Maria-Grazia" last="Martinoli">Maria-Grazia Martinoli</name><affiliation wicri:level="1"><nlm:affiliation>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec, Canada .</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25625827</idno><idno type="pmid">25625827</idno><idno type="doi">10.1089/rej.2014.1639</idno><idno type="wicri:Area/PubMed/Corpus">000493</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000493</idno><idno type="wicri:Area/PubMed/Curation">000493</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000493</idno><idno type="wicri:Area/PubMed/Checkpoint">000493</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000493</idno><idno type="wicri:Area/Ncbi/Merge">001A45</idno><idno type="wicri:Area/Ncbi/Curation">001A45</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A45</idno><idno type="wicri:Area/Main/Merge">000736</idno><idno type="wicri:Area/Main/Curation">000735</idno><idno type="wicri:Area/Main/Exploration">000735</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?</title><author><name sortKey="Renaud, Justine" sort="Renaud, Justine" uniqKey="Renaud J" first="Justine" last="Renaud">Justine Renaud</name><affiliation wicri:level="1"><nlm:affiliation>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec, Canada .</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Nabavi, Seyed Fazel" sort="Nabavi, Seyed Fazel" uniqKey="Nabavi S" first="Seyed Fazel" last="Nabavi">Seyed Fazel Nabavi</name><affiliation wicri:level="1"><nlm:affiliation>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran, Iran .</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Daglia, Maria" sort="Daglia, Maria" uniqKey="Daglia M" first="Maria" last="Daglia">Maria Daglia</name><affiliation wicri:level="1"><nlm:affiliation>3 Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia , Italy .</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>3 Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia </wicri:regionArea><wicri:noRegion>University of Pavia </wicri:noRegion></affiliation></author><author><name sortKey="Nabavi, Seyed Mohammad" sort="Nabavi, Seyed Mohammad" uniqKey="Nabavi S" first="Seyed Mohammad" last="Nabavi">Seyed Mohammad Nabavi</name><affiliation wicri:level="1"><nlm:affiliation>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran, Iran .</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences , Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Martinoli, Maria Grazia" sort="Martinoli, Maria Grazia" uniqKey="Martinoli M" first="Maria-Grazia" last="Martinoli">Maria-Grazia Martinoli</name><affiliation wicri:level="1"><nlm:affiliation>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec, Canada .</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Medical Biology and Research Group in Neuroscience, Université du Québec , Trois-Rivières, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></analytic><series><title level="j">Rejuvenation research</title><idno type="eISSN">1557-8577</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Catechin (analogs & derivatives)</term><term>Catechin (therapeutic use)</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term><term>Prognosis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Catechin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Catechin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Prognosis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is the second most common neurodegenerative disease, and it is characterized by the loss of the neurotransmitter dopamine and neuronal degeneration in the substantia nigra pars compacta. Thus far, current therapeutic strategies have failed to address neuronal degeneration. It has been reported that overproduction of reactive oxygen species, resulting in oxidative stress, and neuroinflammation play an important role in neurodegenerative diseases through the induction of macromolecular oxidative damage and modulation of intracellular signaling pathways concurring to neuronal cell death. Indeed, anti-oxidant and anti-inflammatory drugs have been the subject of recommendation as a complementary therapy alongside an effective symptomatic treatment to hamper the progression of PD. Today, much attention is paid to polyphenols in light of their potent capacity to reduce oxidative stress and inflammation, while having much fewer side effects than most other drugs. Camellia sinensis L. is the most common ancient herbal tea prepared as a beverage worldwide and it possesses numerous beneficial effects on human health. Epigallocatechin-3-gallate is the best-known bioactive component of C. sinensis and is recognized to exert potent neuroprotective effects against oxidative stress, neuroinflammation, protein aggregation, autophagy, and neuronal cell death in vitro as well as in vivo. The present review appraises the available literature on the beneficial role of epigallocatechin-3-gallate pertaining to dopaminergic degeneration characteristic of PD with particular emphasis on its possible mechanisms of action.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Iran</li><li>Italie</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Renaud, Justine" sort="Renaud, Justine" uniqKey="Renaud J" first="Justine" last="Renaud">Justine Renaud</name></noRegion><name sortKey="Martinoli, Maria Grazia" sort="Martinoli, Maria Grazia" uniqKey="Martinoli M" first="Maria-Grazia" last="Martinoli">Maria-Grazia Martinoli</name></country><country name="Iran"><noRegion><name sortKey="Nabavi, Seyed Fazel" sort="Nabavi, Seyed Fazel" uniqKey="Nabavi S" first="Seyed Fazel" last="Nabavi">Seyed Fazel Nabavi</name></noRegion><name sortKey="Nabavi, Seyed Mohammad" sort="Nabavi, Seyed Mohammad" uniqKey="Nabavi S" first="Seyed Mohammad" last="Nabavi">Seyed Mohammad Nabavi</name></country><country name="Italie"><noRegion><name sortKey="Daglia, Maria" sort="Daglia, Maria" uniqKey="Daglia M" first="Maria" last="Daglia">Maria Daglia</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000735 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000735 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25625827
|texte= Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25625827" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |